SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Acquisition

1 May 2015 07:00

RNS Number : 9497L
Oxford Instruments PLC
01 May 2015
 



 

Release date: 1 May 2015

 

Oxford Instruments plc

Acquisition of Medical Imaging Resources, Inc.

 

Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces the acquisition of Medical Imaging Resources, Inc. (MIR).

 

Founded in 1990 in Ann Arbor Michigan by CEO John Vartanian, MIR specialises in the build, lease and service of mobile medical imaging labs ("mobiles").

 

The mobile labs are built in MIR's factory, with Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) systems from Siemens, GE, Philips and Toshiba. These are leased to customers across the USA. MIR is also responsible for servicing its mobiles. Customers include hospitals and clinics that need additional capacity or that wish to trial MRI or CT machines without committing to the infrastructure and cost associated with a permanent unit.

 

MIR will form a part of OIHealthcare, within the Group's Service sector, which already services GE MRI and CT machines in the USA. There are a number of synergies with OIHealthcare:

 

· This will be a significant step to making OIHealthcare a multi-skilled independent service provider able to support large individual service contracts;

· Access to OIHealthcare's parts and its purchasing power for complete systems will lower MIR's operating costs;

· There will be overheads savings in those areas where duplication is eliminated;

· MIR currently sub-contracts a significant portion of the service work for its mobiles. OIHealthcare staff are located in numerous states and once trained will take over the work and will be able to bring the margin in-house.

 

Consideration, which will be satisfied from existing facilities, comprises $10.4 million (c. £6.8 million) on completion followed by a further $10.1 million (c. £6.6 million) earn-out payable one year later. MIR has approximately $3.0 million (c. £2.0 million) net debt at completion.

 

In the year to 31 December 2014, MIR had sales of $16.6 million (c. £10.8 million), profit before tax of $2.8 million (c. £1.8 million) and EBITDA of $5.6 million (c. £3.6 million). At 31 December 2014, MIR had gross assets of $9.4 million (c. £6.1 million).

 

 

 

Jonathan Flint (Chief Executive) and Kevin Boyd (Finance Director) will host a conference call for analysts and investors on this announcement at 9:30 am (UK time), today 1 May. To join the call, please use the dial-in numbers below:

 

Dial: +44 (0)20 3139 4830

PIN: 89662683#

 

 

 

- Ends -

 

Enquiries:

 

 

Oxford Instruments plc Tel: 01865 393200

Jonathan Flint, Chief Executive

Kevin Boyd, Group Finance Director

 

MHP Tel: 020 3128 8100

Rachel Hirst / Jack Holden

 

Issued for and on behalf of Oxford Instruments plc

 

 

 

Notes to Editors  

 

About Oxford Instruments plc

Oxford Instruments designs, supplies and supports high-technology tools and systems with a focus on research and industrial applications. Innovation has been the driving force behind Oxford Instruments' growth and success for over 50 years, and its strategy is to effect the successful commercialisation of these ideas by bringing them to market in a timely and customer-focused fashion.

The first technology business to be spun out from Oxford University, Oxford Instruments objective is to be the leading provider of new generation tools and systems for the research and industrial sectors with a focus on nanotechnology. Its key market sectors include nano-fabrication and nano-materials. The company's strategy is to expand the business into the life sciences arena, where nanotechnology and biotechnology intersect.

This involves the combination of core technologies in areas such as low temperature, high magnetic field and ultra high vacuum environments; Nuclear Magnetic Resonance; x-ray, electron, laser and optical based metrology; atomic force microscopy; optical imaging; advanced growth, deposition and etching.

Oxford Instruments aims to pursue responsible development and deeper understanding of our world through science and technology. Its products, expertise, and ideas address global issues such as energy, environment, security and health.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEAFLEDSDSEAF
Date   Source Headline
6th Jun 20172:14 pmPRNTotal Voting Rights
4th May 20171:56 pmPRNTotal Voting Rights
26th Apr 20177:30 amRNSSale of Industrial Analysis business to HHT
13th Apr 20177:00 amRNSTrading Statement
3rd Apr 20173:25 pmPRNTotal Voting Rights
27th Feb 20179:34 amPRNHolding(s) in Company
2nd Feb 20171:25 pmPRNTotal Voting Rights
31st Jan 20174:31 pmPRNHolding(s) in Company
30th Jan 20174:43 pmPRNHolding(s) in Company
3rd Jan 201711:30 amPRNBlocklisting - Interim Review
18th Nov 20167:00 amRNSDisposal
15th Nov 20167:00 amRNSHalf-year Report
14th Nov 201612:52 pmPRNDirector Declaration
1st Nov 201611:07 amPRNTotal Voting Rights
26th Oct 20167:00 amPRNHolding(s) in Company
14th Sep 201610:17 amPRNResult of AGM
13th Sep 20167:00 amRNSAGM Statement
1st Aug 20164:14 pmPRNTotal Voting Rights
5th Jul 20161:26 pmPRNTotal Voting Rights
5th Jul 20161:19 pmPRNBlocklisting - Interim Review
21st Jun 20162:51 pmPRNDirector/PDMR Shareholding
15th Jun 20167:00 amRNSFinal Results
13th Jun 20161:44 pmPRNDirector/PDMR Shareholding
7th Jun 20163:31 pmRNSDirectorate Change
12th May 20164:26 pmPRNDirector/PDMR Shareholding
9th May 20167:00 amRNSDirectorate Change
18th Apr 20167:00 amPRNDirector/PDMR Shareholding
11th Apr 201610:49 amPRNDirectorate Change
14th Mar 20163:54 pmPRNDirector/PDMR Shareholding
3rd Mar 201611:03 amPRNHolding(s) in Company
24th Feb 20163:47 pmPRNHolding(s) in Company
24th Feb 20167:00 amRNSDirector Declaration & Directorate Change
23rd Feb 201611:52 amPRNNotification of Home State
16th Feb 201611:07 amPRNDirector/PDMR Shareholding
12th Feb 20167:00 amRNSAppointment of Group Finance Director
2nd Feb 20167:00 amRNSAppointment of Non-Executive Director
22nd Jan 20167:00 amRNSTrading Statement
15th Jan 20167:00 amRNSNotice of Trading Update
14th Jan 20161:51 pmPRNDirector/PDMR Shareholding
4th Jan 201612:07 pmPRNBlocklisting - Interim Review
1st Dec 201510:37 amPRNHolding(s) in Company
26th Nov 20153:41 pmPRNHolding(s) in Company
24th Nov 20157:00 amRNSDisposal
12th Nov 20152:23 pmPRNDirector/PDMR Shareholding
10th Nov 20153:23 pmPRNHolding(s) in Company
10th Nov 20157:01 amRNSDirectorate Changes
10th Nov 20157:00 amRNSHalf Yearly Report
27th Oct 201510:06 amRNSReplacement re: Directorate Change
27th Oct 20157:00 amRNSDirectorate Change
14th Oct 201511:09 amPRNDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.